Nigel Hawkes helpfully summarises the patent position of Seroquel in
BMJ news item. It's lost its patent for the XL (prolonged release) version in the UK, which has been marketed as an add-on in depression (see
previous post). At least sense has prevailed about the issue of exclusivity of information about side effects, but maybe I'm keen to thwart AstraZeneca, like the FDA apparently.
No comments:
Post a Comment